MARKET

VERA

VERA

Vera Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.99
-0.58
-2.82%
After Hours: 20.40 +0.41 +2.05% 17:49 01/14 EST
OPEN
20.01
PREV CLOSE
20.57
HIGH
20.82
LOW
19.25
VOLUME
58.29K
TURNOVER
--
52 WEEK HIGH
37.11
52 WEEK LOW
11.30
MARKET CAP
425.34M
P/E (TTM)
-7.0249
1D
5D
1M
3M
1Y
5Y
65 Biggest Movers From Yesterday
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index.
Benzinga · 12/21/2021 10:25
These are the top 10 best performing newly public Bay Area stocks
The parade to Wall Street was the biggest in decades, if ever, in 2021. But the portion of newly public companies that actually posted positive returns was a small fraction. Among the Bay Area contingent, these did the best.
American City Business Journals · 12/21/2021 00:26
Vera Therapeutics gives back gains from Friday's Pfizer deal; closes down 18%
Vera (NASDAQ:VERA) has more than given back gains it made on Friday following the acquisition of a monoclonal antibody candidate from Pfizer (NYSE:PFE), closing down 18%. The deal with Pfizer is
Seekingalpha · 12/20/2021 21:37
Vera Therapeutics (VERA) Sees Hammer Chart Pattern: Time to Buy?
Zacks.com · 12/17/2021 12:54
BRIEF-Vera Therapeutics Announces Acquisition Of Monoclonal Antibody From Pfizer To Treat BK Virus In Transplant Patients
reuters.com · 12/17/2021 12:34
Vera Therapeutics Reports Purchase Of Monoclonal Antibody From Pfizer For $5M Upfront Payment, Potential Milestones For Up To $7M
Ongoing Phase 2 clinical trial for MAU868 in kidney transplant patients; potential first-in-class   MAU868 Phase 2 data for kidney transplant to readout mid-2022 BK Virus is a leading cause of transplant loss and
Benzinga · 12/17/2021 12:31
BRIEF-Vera Therapeutics Appoints Kimball Hall To Board Of Directors
reuters.com · 12/14/2021 12:40
Inotiv, Theravance Biopharma leads healthcare gainers; Radius Health, Ensysce Biosciences among major losers
Gainers: Inotiv (NASDAQ:NOTV) +13%, Theravance Biopharma (NASDAQ:TBPH) +11%, Biofrontera (NASDAQ:BFRA) +11%, Dare Bioscience (NASDAQ:DARE) +10%, Stereotaxis, Inc. (NYSE:STXS) +8%. Losers: Radius Health RDUS -43%, Ensysce Biosciences (NASDAQ:ENSC) -27%, Cor...
Seekingalpha · 12/08/2021 16:13
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VERA. Analyze the recent business situations of Vera Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VERA stock price target is 49.67 with a high estimate of 89.00 and a low estimate of 25.00.
High89.00
Average49.67
Low25.00
Current 19.99
EPS
Actual
Estimate
-9.78-7.34-4.89-2.45
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 30
Institutional Holdings: 13.77M
% Owned: 64.70%
Shares Outstanding: 21.28M
TypeInstitutionsShares
Increased
7
599.98K
New
16
280.39K
Decreased
3
496.89K
Sold Out
7
186.06K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Non-Executive Chairman/Independent Director
Kurt Von Emster
Chief Executive Officer/Founder/Director
Marshall Fordyce
Chief Financial Officer
Sean Grant
Senior Vice President
Tom Doan
Executive Officer
Joanne Curley
Executive Officer
Lauren Frenz
Other
Celia Lin
Director
Kimball Hall
Independent Director
Andrew Cheng
Independent Director
Patrick Enright
Independent Director
Maha Katabi
Independent Director
Scott Morrison
Independent Director
Beth Seidenberg
No Data
About VERA
Vera Therapeutics, Inc. is a clinical stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a biologic inhibitor of B cells and plasma cells. Atacicept is self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease and early death. It is also developing MAU868, a monoclonal antibody that neutralizes infection with BK Virus.

Webull offers kinds of Vera Therapeutics Inc stock information, including NASDAQ:VERA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VERA stock methods without spending real money on the virtual paper trading platform.